Navigation Links
NeurogesX Reports First Quarter 2008 Results
Date:5/15/2008

Highlights:

- IND for liquid formulation, NGX-1998, expected to be opened and commencement of clinical development expected in second quarter of 2008 - NDA submission for dermal patch, NGX-4010, in PHN expected in second half

of 2008

- NGX-4010 MAA under EMEA review for peripheral neuropathic pain

SAN MATEO, Calif., May 15 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the first quarter of 2008.

Anthony DiTonno, President and CEO, commented, "We are focused on achieving our overall goal of receiving marketing approval for our lead product candidate, NGX-4010 in the United States and Europe. Following our recent meeting with the U.S. Food and Drug Administration (FDA), we believe that we are on track to file a new drug application (NDA) later this year for the postherpetic neuralgia (PHN) indication. Our marketing authorization application (MAA) was accepted by the European Medicines Agency (EMEA) in September of last year under the centralized procedure. We have been granted an extension for our response to the Day 120 questions in order to include additional clinical data and plan to submit our response in the third quarter of 2008."

Mr. DiTonno continued, "During the second quarter of 2008, we plan to open an investigational new drug (IND) application for our second product candidate, NGX-1998, a liquid formulation of capsaicin, the same active ingredient in our lead product candidate, NGX-4010. We are evaluating our clinical program for NGX-1998 in a range of neuropathic pain conditions."

F
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. NeurogesX to Report First Quarter 2008 Financial Results
2. NeurogesX to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
3. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
4. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
5. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
6. NeurogesX Closes $25 Million Private Placement
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
9. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10. NeurogesX Expands Senior Management Team
11. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
(Date:1/14/2014)... 2014 During the 1600’s through the 1800’s ... Doctor’s Plague.” In this time period, doctors did not know ... times, to the death of vulnerable patients. In the same ... they may be unwittingly transmitting herpes viruses to their patients. ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
(Date:1/14/2014)... Translational Biosciences, a subsidiary of ... trial approval for the treatment of rheumatoid arthritis ... from the Comité Nacional de Bioética de la ... (RA) is an autoimmune disease in which the ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... - DAPTACEL vaccine is licensed for the entire immunization ... protect against diphtheria, tetanus, and pertussis -, ... Pasteur, the vaccines division of the sanofi-aventis Group,announced today ... DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular,Pertussis Vaccine Adsorbed) ...
... Silence Therapeutics plc,(AIM: SLN) today announces a collaboration ... a range of novel approaches for the delivery,of ... leading,expertise in the delivery of siRNA molecules, in ... siRNA in vivo using its,proprietary AtuPLEX technology. The ...
... March 13 Proteon Therapeutics, Inc.,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... appointed,Gregory D. Phelps, a seasoned biopharmaceutical executive, ... brings more than 30 years of executive,leadership ...
Cached Biology Technology:U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 2U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 3U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 4Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2
(Date:4/20/2014)... lung, breast and pancreatic cancers also promote drug-resistance and ... California, San Diego School of Medicine have discovered a ... drug-resistant tumors that appears responsible for inducing tumor metastasis ... , The findings, published in the April 20, ... may point to new therapeutic opportunities for reversing drug ...
(Date:4/18/2014)... contraceptive pills in Peru found that 28 percent ... quality or falsified. Many pills released the active ... ingredient. One batch had no active ingredient at ... researchers at the Georgia Institute of Technology developed ... assess suspected counterfeit drugs and then characterize their ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... that bacteria that cause diseases like bubonic plague and ... them infectious on or off. , Knowing how disease-causing ... may one day help scientists create drugs that control ... harmless, said Vladimir Svetlov, a study co-author and a ...
... how a protein from a bacterium acts like a cunningly ... of a new range of natural insecticides. It had been known that ... of a bacterium which they harbour inside their intestine. , The ... the nematode to kill and feed on the dead body of the ...
... reveal how illusions are produced in the brain's visual cortex, ... evidence of rapid integration of auditory and visual sensations in ... neural mechanisms by which visual perception can be altered by ... 12 edition of the Journal of Neuroscience. , When ...
Cached Biology News:Bacteria control how infectious they become, study finds 2Bacteria control how infectious they become, study finds 3Secret of worm's poison pill box protein could produce new natural insecticide 2Wired for sound: How the brain senses visual illusions 2
...
... supplies, for 10 chips, provides the ... standard-sensitivity RNA analysis (nanogram levels) with ... electrophoresis system. Supplied are 1,250 microliters ... stain, 20 microliters RNA ladder, 900 ...
MAb to Verotoxin II (SLT-2a) Verotoxin II (Shiga-like) A subunit (SLT-2a)...
...
Biology Products: